Please login to the form below

Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

Herceptin biosimilars can’t make Perjeta cost effective, says NICE. NICE has once again rejected Roche’s HER2-positive breast cancer drug Perjeta for treating patients after surgery in those who ... NICE already recommends Perjeta with trastuzumab

Latest news

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

Perjeta sales continued to grow, specifically in the metastatic and neoadjuvant settings, rising to 1.3bn swiss francs in global sales.
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

Roche picked up an important new approval recommendation for its HER2-targeting drug Perjeta (pertuzumab) as an adjuvant (post-surgery) treatment for HER2-positive breast cancer at high risk of recurrence ... The FDA approved adjuvant use of Perjeta last
Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

MS drug Ocrevus and breast cancer treatment Perjeta were the main drivers in its pharma division.
MSD launches EU’s first biosimilar Herceptin in UK

has insisted it can ride out the storm with new products such as multiple sclerosis therapy Ocrevus (ocrelizumab) and cancer drugs Perjeta (pertuzumab), Tecentriq (atezolizumab) and Alecensa (alectinib).
Roche faces biosimilar blitz in 2018

Last year, Ocrevus, Tecentriq, Perjeta and Alecensa sales drove a 5% growth for Roche, along with label extensions for existing products and approvals for new medicines Ocrevus and Hemlibra in the ... US. Schwan added: “I am particularly pleased with

More from news
Approximately 17 fully matching, plus 43 partially matching documents found.

Latest Intelligence

Back to the future

In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Healthcare PR Senior Account Manager: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Graduate Scientific Editor: DOE

Account Manager: Negotiable

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Market Access Consultant - Greater Manchester: Negotiable

Medical Writer - Creative and Scientific Projects: DOE

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Associate Scientific Director: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Manager- 4 days per week or full-time: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Systematic Review Lead- London: Negotiable

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Medical Writer: Salary is DOE

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Subscribe to our email news alerts

PMHub

Add my company

Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...